Hims & Hers Stock Drops as FDA Says Ozempic and Wegovy No Longer in Short Supply
Hims & Hers Health shares swooned after the Food & Drug Administration said the active ingredient in Ozempic and Wegovy is no longer in short supply. The company makes compounded versions of weight-loss drugs under an FDA rule that applies when the ...
17hon MSN
The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.
The U.S. FDA has officially declared that Novo Nordisk’s (NVO) popular diabetes and weight loss therapies, Ozempic and Wegovy ...
HIMS stock plunged by 18% after the FDA news that resolved a shortage of weight-loss drugs like Ozempic and Wegovy, which ...
Hims & Hers Health (NYSE:HIMS – Get Free Report) is projected to announce its earnings results after the market closes on ...
Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
Hims & Hers Health acquired a peptide facility to strengthen its U.S. supply chain and meet demand for personalized ...
We believe there is minimal cause for concern with HIMS stock, which makes it attractive but highly sensitive to adverse events as its current valuation is extremely ...
Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...
Hims & Hers Health Inc. has acquired a California-based manufacturing facility to expand its range of peptide treatments, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback